Incyte Corporation has announced it will not proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667, its selective CDK2 inhibitor, in combination with bevacizumab as first-line maintenance therapy in patients with ovarian cancer. This study was expected to begin in the fourth quarter of 2026.

The decision to halt the study is part of a strategic prioritization of Incyte's clinical development portfolio. Importantly, the company stated that this decision was not influenced by any safety or efficacy findings from the INCB123667 clinical program. Furthermore, Incyte does not expect this change to affect its financial guidance or its previously disclosed long-term outlook.

Background

Incyte Corporation, incorporated in Delaware, operates within the services-commercial physical and biological research sector, as classified under SIC code 8731. The company is publicly traded on the Nasdaq under the ticker symbol INCY. Recent filings include a Form 8-K on November 13, 2026, detailing this latest development.

What the Filing Says

"Incyte Corporation has decided not to proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667... The Company’s determination was based on the prioritization of its clinical development portfolio and was not based on any safety or efficacy findings from the INCB123667 clinical program."

Impact

This decision may impact various stakeholders, including investors, healthcare providers, and patients involved in clinical trials for ovarian cancer treatments. However, Incyte has reassured that the decision will not alter its financial projections.

What's Next

The filing does not say what happens next.